- 1 Efficacy and safety of TiNO-coated stents versus drug-eluting
- 2 coronary stents. Systematic literature review and meta-analysis.
- 3 Frederic C. Daoud, MD, MSc^a, Louis Létinier, MD, MSc^a, Nicholas Moore, MD, PhD^a, Pierre
- 4 Coste, MD^b, Pasi P. Karjalainen, MD, PhD^c

5

6 **Short title:** TiNO-coated stents *versus* DES meta-analysis

7

- 8 Affiliations
- 9 ^a Univ. Bordeaux, INSERM, BPH, U1219, F-33000, Bordeaux, France
- ^b Coronary Care Unit, Cardiologic Hospital, University of Bordeaux, Pessac, France
- ^c Cardiac unit, Heart and Lung Center, Helsinki University Hospital and Helsinki University,
- 12 Helsinki, Finland

13

- 14 Address for correspondence
- Frederic C. Daoud, M.D., M.Sc.
- 16 orcid.org/0000-0002-0469-9723
- 17 Université de Bordeaux
- 18 Unité de Pharmacologie clinique
- 19 INSERM U1219 Bordeaux Population Health Center
- 20 Bâtiment 1A, 1er étage, Case 36
- 21 146 rue Léo Saignat
- 22 33076 Bordeaux Cedex, France
- 23 Tel. +33 (0)5 57 57 15 60, Fax +33 (0)5 57 57 46 71 06
- 24 E-mail: frederic.daoud-pineau@u-bordeaux.fr

25

- 26 Manuscript file word count: 5,843
- 27 Figures: 3
- 28 **Tables**: 2
- 29 **Abstract word count:** 295

31 Abstract

- Objectives: To compare clinical outcomes after percutaneous coronary intervention (PCI) using
- titanium-nitride-oxide coated stents (TiNOS) versus drug-eluting stents (DES) in coronary artery
- disease (CAD) including acute coronary syndrome (ACS).
- 35 Design: Prospective systematic literature (SLR) conducted according to PRISMA. Medline,
- Embase, Cochrane, Web of Science were searched in March 2018 and updated.
- 37 Setting: Interventional cardiology.
- Participants: Patients with CAD, including ACS, requiring PCI.
- 39 Interventions: All prospective randomized controlled trials (RCTs) that compared clinical
- 40 outcomes after PCI with DES versus TiNOS.
- Outcome measures: The pooled risk ratios (RR), TiNOS over DES, with 95% confidence
- 42 intervals (CI) are computed for device-oriented Major Adverse Cardiac Events (MACE), non-
- fatal myocardial infarction (MI), cardiac death (CD), clinically driven target lesion
- revascularization (TLR), probable or definite stent thrombosis (ST), total mortality, at one to five
- 45 years after PCI. Pooled RRs are stratified according to baseline ACS versus other CAD.
- Sensitivity analysis (SA) and certainty of the evidence are rated per GRADE.
- 47 Results: Five RCTs are eligible with 1,855 patients with TiNOS versus 1,363 with DES at 1-year
- follow-up and 783 versus 771 at 5-year. Three RCTs included patients with ACS only. One-year
- 49 RRs in ACS are: MACE 0.93 [0.72, 1.20], MI 0.48 [0.31, 0.73], CD 0.66 [0.33, 1.31], TLR 1.55
- 50 [1.10, 2.19] and ST 0.35 [0.20, 0.64]. One-year MACE, MI, and ST are robust to SA. The
- certainty of the evidence is high in MACE, moderate in MI, and low or very low in the other
- 52 endpoints. There are too few observations to conclude about other CAD and 5-year outcomes.
- However, 5-year interim results are consistent with 1-year conclusions.
- Conclusions: A similar risk of MACE is found in TiNOS and DES, with potentially fewer MI
- and ST but more TLR in TiNOS. TiNOS are safe and effective in ACS at 1-year follow-up.

57 Registration: PROSPERO CRD42018090622

56

58

Strengths and limitations of this study

- Strengths:

59

60

63

64

65

66

67

68

69

- The level of certainty of the evidence is high for the primary endpoint at one-year follow-up in patients treated for acute coronary syndrome.
 - The primary endpoint and critical secondary endpoints are robust to sensitivity analysis.
 - Limitations:
 - Outcomes in patients treated for chronic coronary artery disease cannot be analyzed.
 - o The level of certainty of the evidence of secondary endpoints is moderate or low.
 - o Analysis of five-year outcomes is still at an interim stage.

71	
72	Objectives
73	Percutaneous coronary interventions (PCI) with drug-eluting stents (DES) is the standard of care
74	in Coronary Artery Disease (CAD), including Acute Coronary Syndrome (ACS). 1-6 mTOR
75	inhibitors such as everolimus and paclitaxel have been the main drug types used on stents to
76	inhibit post-stenting restenosis. ⁷⁻⁹ Their side effect is the increased risk of stent thrombosis (ST),
77	requiring prolonged Dual AntiPlatelet Therapy (DAPT) with its own risk of complications. 10,11
78	Titanium-nitride-oxide coated coronary stents (TiNOS), also designated "bioactive stents" (BAS)
79	have a pharmacologically inactive, non-absorbable coating. Preclinical data has shown less
80	neointimal hyperplasia with TiNOS than with bare-metal stents (BMS). 12,13,14
81	Several trials comparing TiNOS with DES have been conducted but no systematic review of that
82	evidence has been published so far.
83	
84	Participants – Interventions - Outcome measures
85	The question was specified using the PICOS framework ¹⁵ : P atients presented CAD including
86	ACS. <u>I</u> ntervention was PCI using TiNOS. <u>C</u> omparator was PCI using DES. <u>O</u> utcomes were the
87	device-oriented Major Adverse Cardiac Events (MACE) and the components of that composiste
88	i.e., Cardiac death (CD), recurrent myocardial infarction (MI), and clinically driven target lesion
89	revascularization (TLR). Probable or definite ST, and all-cause mortality ("total death": TD)

were also analyzed. Outcomes were assessed at 1-year and 5-year follow-ups. **S**tudy methods

were prospective randomized controlled clinical trials (RCTs).

Methods

This systematic literature review (SLR) is the first to compare the efficacy and safety of TiNOS *versus* DES in CAD. It was designed and conducted according to methods described in the Cochrane Handbook with the use of "Grading of Recommendations Assessment, Development and Evaluation" (GRADE). The protocol was registered in PROSPERO (CRD4201809062) before initiation. It is reported according to "Preferred Reporting Items for Systematic Reviews and Meta-Analyses" (PRISMA). ¹⁶⁻¹⁸

Data recording and the meta-analysis were conducted in RevMan 5.3 (Review Manager Version 5.3 software. Copenhagen, Denmark: The Nordic Cochrane Centre, 2014). The certainty of evidence according was rated with GRADEpro GDT software 2020 on-line version, (https://gradepro.org). Additional analyses were performed in STATA 16 (StataCorp LP, College Station, Tx, USA) using the metan and metaprop packages.

Data sources

MEDLINE, EMBASE, the Cochrane Library, and Web of Science (WoS) electronic databases, were queried on March 8, 2018, using their search engines. The search terms were: ((bioactive OR (Titanium AND nitride AND oxide) OR TiNO OR TNO OR BAS) AND stent) AND (DES OR (drug AND eluting AND stent)) AND (RCT OR ((randomized OR randomised) AND controlled AND trial)). No exclusion filter was applied related to language, country, year, or any other aspect. The websites of AHA, TCT, ESC, EuroPCR, and clinicaltrials.gov were also searched. The queries were updated on July 22, 2020, when all initially identified RCTs were published to retrieve new evidence if any, from RCTs meeting the PICOS specifications of this SLR. The downloaded record files were imported and pooled and sifted in EndNote X8 (Clarivate Analytics, Philadelphia, PA, USA). One reference only was selected when duplicates were

identified. When differerent references concerned the same study, their information was pooled using the citation of the most recent one. Full articles were reviewed for all references.

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

117

118

Study selection and Data extraction

Two reviewers (FD and LL) performed independently the following steps: (1)Exhaustive reference screening, (2) Reference classification according to the inclusion and exclusion criteria, (3) Extraction of study methods, (4) Patient baseline data, (5) Treatment data and results of each eligible RCT, (6) Individual eligible RCT risk of bias rating, (7) Assessment of the certainty of the evidence for each outcome variable according to GRADE. The results were recorded in RevMan 5.3 file. Differences were adjudicated by a third reviewer (NM). The similarity of the definitions of endpoints across the RCTs was discussed with one investigator (PK). The risk of bias of individual RCTs was rated according to the criteria proposed by the Cochrane Collaboration with operator blinding as a separate item. The screened studies were included if they met the following criteria: First-hand clinical evidence with prospective inclusion; patients with CAD treated with coronary PCI; implantation of either TiNOS or DES after the random allocation of the stent type; target outcomes reported at 1-year and/or 5-year follow-up; the outcomes reported as the number of patients who were included along with the number or proportion of them who presented an event of interest. Studies were ruled out if any of the study selection criteria were not met or if IRB/ethics committee approval and patient informed consent were not explicitly required.

The term ACS referred to patients who presented at baseline with ST-elevated myocardial infarction (STEMI), or non-ST-elevated myocardial infarction (NSTEMI), or unstable angina pectoris.

The definitions of outcomes aimed in this SLR protocol are those defined by the Academic Research Consortium (ARC). Data extraction is stratified according to patient clinical

Statistical analysis

presentation, i.e., ACS versus with other CAD.

The two treatment arms are compared for each endpoint using the risk ratio (RR) defined as ((n patients with an event in TiNOS)/(n patients in TiNOS)/(n patients with an event in DES)/(n patients in DES)). As a result, RR > 1 reflects a higher frequency of events in the TiNOS arm than in the DES arm and conversely. Outcomes are analyzed on an intention-to-treat (ITT) basis. The numerator is the number of patients presenting an event and counted in the treatment arm they were randomized to and the denominator is the sample size of the corresponding arm. For each endpoint, individual study RRs are calculated with their 95% confidence interval (CI [,]) and their degree of heterogeneity is determined. If no significant heterogeneity is detected, the pooled RR is calculated with its CI using the M-H method with a fixed-effect model. \$^{16,20,21}\$ In the case of significant heterogeneity, pooling uses the M-H method with a random-effects model. The pooled analysis is stratified according to baseline clinical presentation, ACS versus other CAD. One-year and 5-year outcomes are analyzed separately. Sensitivity analysis is performed by iteratively recalculating the pooled RR after removing one eligible RCT. As a result, the impact of each RCT on the pooled RR is estimated. It estimates the impact of

160 differences in stent generations and the potential risk of indirection related to differences in outcome definitions. 161 162 Patient and public involvement 163 No patient involved. 164 165 **Results** 166 Overall 167 Study identification, screening, and selection are described in the PRISMA flowchart (Figure 1). 168 One hundred and eleven references were identified and nine publications with first-hand data 169 about five RCTs are eligible for inclusion in the meta-analysis. 170 171 The number of patients with 1-year follow-up data is 1,855 in the TiNOS arm versus 1,363 in the DES arm. Those numbers are 783 versus 773 patients at 5-year follow-up. Three RCTs enrolled 172 only patients presenting with ACS and two enrolled and analyzed jointly patients presenting with 173 174 ACS and other CAD. TIDE enrolled 143 patients with ACS (47%) and TITANIC-XV, 112 (64.7%). The baseline characteristics are summarized in Table 1. Funnel plots and Harbord tests 175 did not detect a risk of publication bias concerning any of the endpoints at 1-year follow-up in all 176 CAD (supplemental material). 177 Four RCTs report or enable to deduct the number of cases of clinically driven TLR, CD, non-178 fatal recurrent MI, and the composite of CD or any non-fatal MI extended or clinically driven 179 TLR. This results in a modified device-oriented MACE where MI "not clearly attributable to a 180 nontarget vessel" is replaced by any MI. Given fatal MIs are counted as CD, this modification 181 adds non-fatal MI in nontarget vessels. 182

183 In one RCT (TITANIC-XV), the primary endpoint is estimated from the available data as the sum of CD, any non-fatal MI, and any TLR assuming no overlap between those variables. 184 The risk of bias in individual RCTs is rated moderate or low except for the operator's knowledge 185 of the type of stent used during the intervention in all RCTs. 186 The pooled RRs of all outcomes at 1-year and 5-year follow-up are reported in Table 2 with CIs 187 and sensitivity analyses. Results are reported overall and in the ACS subgroup. Given the 5-year 188 follow-up of patients in the TIDES-ACS trial is ongoing, pooled RRs for 5-year outcomes are 189 190 interim results. The stratified (ACS relative to other CAD) pooled RRs of effectiveness endpoints show no 191 significant difference in 1-year MACE and a significantly higher rate of TLR with TiNOS 192 (Figure 2). The stratified stratified pooled RRs of safety endpoints show no significant difference 193 in 1-year CD, but significantly lower rates in non-fatal, MI and ST with TiNOS compared to 194 DES (Figure 3). The pooled RR of TD is also not significant (supplemental file). 195 The stratified pooled RRs analysis shows a much larger number of patients in the ACS subgroup 196 compared to the other CAD subgroup (85.2% versus 14.8%). The overall effects are driven by 197 198 the ACS subgroup. The results of the other CAD subgroup (TIDE and TITANIC-XV) are not interpretable because outcomes in patients with ACS are not reported separately. Therefore, the 199 subsequent steps of this SLR are refocused on RCT about ACS only. 200 201 ACS at 1-year follow-up The pooled RRs of effectiveness and safety endpoints in MACE are consistent with overall 202 results but heterogeneity, robustness to sensitivity analysis (Table 2) and the level of certainty of 203

the underlying evidence according to GRADE (supplemental material) need to be assessed separately.

The RR of MACE presents no significant heterogeneity, is robust to sensitivity analysis, and the certainty of evidence is rated high. The RR of clinically driven TLR presents no significant heterogeneity but results are not robust to sensitivity analysis, and the certainty of the evidence is rated low.

The pooled RRs of CD and TD present significant heterogeneity, are not robust to sensitivity analysis, and the certainty of the evidence is rated very low.

The pooled RR of non-fatal MI presents no significant heterogeneity, is robust to sensitivity analysis, and the certainty of the evidence is rated moderate.

The pooled RR of probable or definite SE presents no significant heterogeneity, is robust to sensitivity analysis, and the certainty of the evidence is rated low.

Discussion

TIDE and TITANIC-XV enrolled 255 patients with ACS but their data are not reported separately from the other patients. The impact of not including them in the ACS subgroup is limited given they represent 7.9% of all patients with ACS. The modified definition of device-oriented MACE results in including non-fatal MIs from nontarget vessels. One can reasonably assume the index stent does not affect those events. Ninety non-fatal MIs are reported. Assuming half of them are related to nontarget vessels (i.e., 45 cases), proportionality with sample size would lead to 27 fewer cases with TiNOS and 18 with DES, which would result in an RR of 0.19 [0.09, 0.42]. The inclusion of nontarget MIs thus results in a dilution that is favorable to DES. If the same numbers cases were removed from the count of MACE, the RR would be 0.98 [0.73,

1.30], which would not change the non-inferiority conclusion. The robustness to sensitivity analysis of the pooled RRs of MACE, MI, and ST in ACS, shows that the differences in DES generations, including the elution of paclitaxel and mTOR inhibitors do not significantly change those results. The interim 5-year pooled results will be updated when the final results of TIDES-ACS are published, but the current results are consistent with 1-year outcomes.

Conclusions

This systematic literature review shows that titanium-nitride oxide coated-coronary stents and drug-eluting stents have a similar risk of device-oriented major adverse cardiac events at one-year follow-up in patients with an acute coronary syndrome. This result is robust and the level of certainty of the evidence is high. It also shows a lower risk of recurrent myocardial infarction and stent thrombosis with titanium-nitride oxide coated-coronary stents than with drug-eluting stents with a potentially higher risk of target lesion revascularization. Interim five-year pooled outcomes are consistent with one-year outcomes. These results show that the titanium-nitride oxide coated-coronary stents are safe and effective in acute coronary syndrome at one-year follow-up.

Table 1 Baseline characteristics

Study	Age & prior e	events		Clinical pro	esentatio	on	Procedural data &	medication		Attrition & cross-overs
Stent		TiNOS	DES		TiNOS	DES		TiNOS	DES	
TITAX-AMI ^{22,23} [NCT00495664]	Patients n age prior MI prior PCI prior CABG	214 64±11 15% 10% 7%	211 64±11 9% 5% 6%	NSTEMI STEMI	61% 39%	54% 46%	stents in culprit lesion n TSL (mm) post-dilation procedural success DAPT 12-months		1.1±0.4 19.2±7.2 35% 98.1%	LFU 1y TINOS: 0 DES: 0 5y TINOS 3 DES: 7
TIDE ²⁴ [NCT00492908]	Patients n age prior MI prior PCI prior CABG	152 65.9±9.0 27.6% 25.7% 7.9%	150 63.4±10.5 28.7% 21.3% 25.3% 2.7%	Stable CAD NSTEMI Unstable angina	57.9% 32.9% 9.2%	42.0% 10.7%	stents in culprit lesion n TSL (mm) device success DAPT 12-months	1.28±0.55 19.3±11.1 93.0%	1.17±0.45 19.6±10.0 94.6%	LFU 1y TiNOS: 0 DES: 2 5y: N.R.
TITANIC-XV ²⁵ [NCT01510509]	Patients n age prior MI prior PCI prior CABG	83 66.5±8.8 10.8% 8.4% 2.4%	90 64.5±10.1 15.6% 11.1% 2.2%	NST ACS Deducted other CAD	69.9% 30.1%	60.0% 40.0%	stents in culprit lesion n TSL (mm) stent failure DAPT 12 months	1.1±0.3 18.72±8.20 N.R.	1.1±0.3 21.63±9.65 N.R.	N.R.
BASE-ACS ^{26,27} [NCT00819923]	patients age prior MI prior PCI prior CABG	417 63±12 13.4% 9.6% 4.8%	410 63±12 9.8% 10.5% 4.1%	NSTEMI STEMI Unstable angina	49.4% 38.8% 11.8%	45.6% 38.8% 15.6%	stents in culprit lesion n TSL (mm) post-dilation stent failure DAPT: Aspirin: protocol indefinite, actual N.R. Clopidogrel: protocol 6 months, actual N.R.		1.14±0.36 20.6±8.2 43.9% 1.0%	LFU 1y TiNOS: 3 DES: 3 5y TiNOS 29 DES: 28
TIDES-ACS ^{28,29} [NCT02049229]	Patients n age prior MI prior PCI prior CABG	989 62.7±10. 7.6% 7.0% 0.6%	502 62.6±10.5 9.0% 6.6% 1.2%	NSTEMI STEMI	46.3% 44.9%	45.0% 47.6%	stents in culprit lesion n TSL (mm) post-dilation stent failure DAPT 12-months		1.14±0.37 20.6±7.2 38.0% 1.0% 86.0%	LFU 1y TiNOS: 7 DES: 4

Table 2 Pooled outcomes with sensitivity analysis

	M-H fixed effects R	R & 95% CI after the	e removal of:			
Endpoint	None: all RCTs included	TITAX-AMI	TIDE	TITANIC-XV	BASE-ACS	TIDES-ACS
ALL CAD: ACS & Other	CAD – 1 year follow-u	p	•	·		
MACE	1.01 [0.81, 1.26]	1.06 [0.83, 1.36]	0.96 [0.75, 1.23]	0.98 [0.78, 1.24]	0.99 [0.76, 1.29]	1.07 [0.82, 1.40]
CD or MI	0.55 [0.39, 0.77]	0.57 [0.39, 0.82]	0.52 [0.36, 0.74]	0.55 [0.39, 0.77]	0.53 [0.36, 0.79]	0.60 [0.40, 0.91]
Non-fatal MI	0.52 [0.36, 0.76]	0.51 [0.33, 0.78]	0.48 [0.31, 0.73]	0.52 [0.35, 0.76]	0.60 [0.38, 0.93]	0.51 [0.32, 0.82]
CD	0.66 [0.33, 1.31]	0.77 [0.37, 1.61]	0.66 [0.33, 1.31]	0.66 [0.33, 1.31]	0.30 [0.11, 0.81]	1.11 [0.43, 2.85]
Clinically driven TLR	1.62 [1.20, 2.18]	1.56 [1.13, 2.15]	1.60 [1.15, 2.24]	1.58 [1.16, 2.14]	1.74 [1.22, 2.47]	1.63 [1.14, 2.33]
Probable or definite ST	0.39 [0.22, 0.69]	0.46 [0.25, 0.84]	0.35 [0.20, 0.64]	0.39 [0.22, 0.69]	0.36 [0.18, 0.72]	0.38 [0.16, 0.87]
Definite ST	0.51 [0.26, 0.99]	0.49 [0.25, 0.97]	0.46 [0.23, 0.92]	0.51 [0.26, 0.99]	0.62 [0.29, 1.36]	0.52 [0.18, 1.44]
TD	0.78 [0.48, 1.27]	0.77 [0.46, 1.32]	0.78 [0.47, 1.27]	0.78 [0.48, 1.27]	0.49 [0.26, 0.95] ^b	1.22 [0.65, 2.28]
ACS only – 1 year follow-u	ıp					
MACE	0.93 [0.72, 1.20]	0.97 [0.73, 1.30]	N.A.	N.A.	0.86 [0.63, 1.19]	0.95 [0.68, 1.33]
CD or MI	0.52 [0.36, 0.75]	0.53 [0.35, 0.80]	N.A.	N.A.	0.48 [0.30, 0.75]	0.56 [0.35, 0.90]
Non-fatal MI	0.48 [0.31, 0.73]	0.45 [0.27, 0.74]	N.A.	N.A.	0.55 [0.33, 0.92]	0.44 [0.25, 0.77]
CD	0.66 [0.33, 1.31]	0.77 [0.37, 1.61]	N.A.	N.A.	0.30 [0.11, 0.81]	1.11 [0.43, 2.85]
Clinically driven TLR	1.55 [1.10, 2.19]	1.46 [0.99, 2.15]	N.A.	N.A.	1.69 [1.09, 2.63]	1.53 [0.97, 2.40]
Probable or definite ST	0.35 [0.20, 0.64]	0.42 [0.22, 0.78]	N.A.	N.A.	0.32 [0.15, 0.65]	0.31 [0.12, 0.77]
Definite ST	0.46 [0.23, 0.92]	0.43 [0.21, 0.89]	N.A.	N.A.	0.54 [0.24, 1.24]	0.39 [0.12, 1.25]
TD	0.78 [0.47, 1.27]	0.77 [0.45, 1.32]	N.A.	N.A.	0.47 [0.24, 0.93] ^b	1.23 [0.64, 2.35]
ALL CAD: ACS & Other	CAD – 5 year follow-u	p - Interim Results				
MACE	0.82 [0.66, 1.02]	0.91 [0.70, 1.19]	0.74 [0.58, 0.95] ^b	N.A.	0.83 [0.62, 1.10]	Expected
CD or MI	0.57 [0.42, 0.77]	0.67 [0.46, 0.97]	0.53 [0.38, 0.73]	N.A.	0.53 [0.35, 0.80]	Expected
Non-fatal MI	0.56 [0.39, 0.80]	0.59 [0.37, 0.92]	0.54 [0.37, 0.80]	N.A.	0.57 [0.35, 0.93]	Expected
CD	0.68 [0.39, 1.19]	0.93 [0.47, 1.82]	0.59 [0.31, 1.11]	N.A.	0.55 [0.25, 1.24]	Expected
Clinically driven TLR	1.01 [0.75, 1.35]	1.00 [0.71, 1.42]	0.94 [0.66, 1.32]	N.A.	1.13 [0.77, 1.66]	Expected
Probable or definite ST	0.30 [0.14, 0.61]	0.45 [0.19, 1.05]	0.25 [0.12, 0.55]	N.A.	0.22 [0.07, 0.70]	Expected
Definite ST	0.25 [0.11, 0.55]	0.37 [0.14, 0.99]	0.20 [0.09, 0.49]	N.A.	0.22 [0.07, 0.70]	Expected
TD	1.03 [0.74, 1.45]	1.14 [0.75, 1.73]	0.95 [0.65, 1.37]	N.A.	1.05 [0.65, 1.69]	Expected
ACS only - 5 year follow-u	ıp - Interim Results					
MACE ^a	0.74 [0.58, 0.95]	0.81 [0.59, 1.12]°	N.A.	N.A.	0.65 [0.44, 0.95]°	Expected
CD or MI	0.53 [0.38, 0.73]	0.61 [0.40, 0.95]	N.A.	N.A.	0.42 [0.25, 0.71]	Expected
Non-fatal MI	0.54 [0.37, 0.80]	0.56 [0.33, 0.94]°	N.A.	N.A.	0.53 [0.30, 0.94] ^c	Expected
CD	0.59 [0.31, 1.11]	0.83 [0.38, 1.84] °	N.A.	N.A.	0.33 [0.11, 1.00] ^c	Expected
Clinically driven TLR	0.94 [0.66, 1.32]	0.88 [0.56, 1.37]°	N.A.	N.A.	1.03 [0.60, 1.76] °	Expected
Probable or definite ST ^a	0.25 [0.12, 0.55]	0.37 [0.15, 0.93]°	N.A.	N.A.	0.13 [0.03, 0.57]°	Expected
Definite ST ^a	0.20 [0.09, 0.49]	0.28 [0.09, 0.85]°	N.A.	N.A.	0.13 [0.03, 0.57] °	Expected
TD	0.95 [0.65, 1.37]	1.02 [0.63, 1.65] °	N.A.	N.A.	0.85 [0.48, 1.53]°	Expected

^a sensitivity analysis in ACS at 5-year follow-up results in the RR and confidence intervals of individual RCTs; ^b borderline shift with 3 or fewer RCTs contributing to the pooled estimate; ^c results based on a single-trial; N.A. Not applicable

Supplemental material: 252 Details of methods applied in this SLR. 253 Methods of individual RCTs 254 Table of the number of patients with events – ITT 255 Funnel plots and results of Harbord tests. 256 Summary of risk of bias in individual RCTs 257 Pooled RR of CD or MI, and TD 258 GRADE certainty of evidence assessment 259 PRISMA checklist 260 261 **Contributors** 262 Frederic Daoud (FD): Main reviewer and meta-analyst with LL. 263 264 Louis Létinier (LL): Main reviewer and meta-analyst with with FD. Nicholas Moore (NM): Third reviewer. Adjudicated disagreements. 265 266 Pierre Coste (PC): Advised on protocol and analysis. Pasi Karjalainen (PK): Provided additional information about the methods of the individual 267 trials. 268 269

271	
272	Funding
273 274	This work was exclusively funded by the University of Bordeaux and INSERM BPH U1219 Bordeaux, France
275	
276	Data sharing statement
277	All data included in this review are published.
278	

279 References

- 1. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis
- SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID,
- Mukherjee D, Ting H, O'Gara PT, Kushner FG, Ascheim DD, Brindis RG, Casey Jr DE 1,
- 283 Chung MK, de Lemos JA, Diercks DB, Fang JC, Franklin BA, Granger CB, Krumholz HM,
- Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE,
- Tommaso CL, Tracy CM, Woo YJ, Zhao DX. 2011 ACCF/AHA/SCAI Guideline for
- 286 Percutaneous Coronary Intervention: a report of the American College of Cardiology
- 287 Foundation/American Heart Association Task Force on Practice Guidelines and the Society for
- 288 Cardiovascular Angiography and Interventions. Circulation. 2011 Dec 6; 124(23):e574-651. doi:
- 289 10.1161/CIR.0b013e31823ba622. Epub 2011 Nov 7. Erratum in: Circulation. 2012 Feb
- 290 28;125(8):e412. Dosage error in article text. PMID: 22064601.
- 291 2. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM,
- Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA,
- Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo
- 294 YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA,
- DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Kushner FG, Ohman EM, Stevenson WG,
- 296 Yancy CW; American College of Cardiology Foundation/American Heart Association Task
- Force on Practice Guidelines.. 2013 ACCF/AHA guideline for the management of ST-elevation
- 298 myocardial infarction: a report of the American College of Cardiology Foundation/American
- Heart Association Task Force on Practice Guidelines. Circulation. 2013 Jan 29; 127(4):e362-
- 300 425. doi: 10.1161/CIR.0b013e3182742cf6. Epub 2012 Dec 17. Erratum in: Circulation. 2013
- 301 Dec 24;128(25):e481. PMID: 23247304.
- 302 3. Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj
- A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx
- N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabaté M, Senior R, Taggart DP, van der
- Wall EE, Vrints CJ; ESC Committee for Practice Guidelines, Zamorano JL, Achenbach S,
- Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D,
- Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli
- 308 MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S;
- 309 Document Reviewers, Knuuti J, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol
- 310 C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Hasdai D,
- Husted S, James SK, Kervinen K, Kolh P, Kristensen SD, Lancellotti P, Maggioni AP, Piepoli
- MF, Pries AR, Romeo F, Rydén L, Simoons ML, Sirnes PA, Steg PG, Timmis A, Wijns W,
- Windecker S, Yildirir A, Zamorano JL. 2013 ESC guidelines on the management of stable
- coronary artery disease: the Task Force on the management of stable coronary artery disease of
- the European Society of Cardiology. Eur Heart J. 2013; 34(38):2949–3003. doi:
- 316 10.1093/eurheartj/eht296. Epub 2013 Aug 30. Erratum in: Eur Heart J. 2014 Sep 1;35(33):2260-
- 317 1. PMID: 23996286.

- 4. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS,
- Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine
- 320 MS, Smalling RW, Zieman SJ; ACC/AHA Task Force Members; Society for Cardiovascular
- Angiography and Interventions and the Society of Thoracic Surgeons. 2014 AHA/ACC guideline
- for the management of patients with non-ST-elevation acute coronary syndromes: a report of the
- 323 American College of Cardiology/American Heart Association Task Force on Practice
- Guidelines. Circulation. 2014; 130(25):2354-2394. doi: 10.1161/CIR.000000000000133. Epub
- 2014 Sep 23. Erratum in: Circulation. 2014 Dec 23;130(25):e431-2. Dosage error in article text.
- 326 PMID: 25249586.
- 5. Collet J, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt D, Dendale P, Dorobantu M,
- Edvardsen T, Folliguet T, Gale C, Gilard M, Jobs A, Jüni P, Lambrinou E, Lewis B, Mehilli J,
- Meliga E, Merkely B, Mueller C, Roffi M, Rutten F, Sibbing D, Siontis G, ESC Scientific
- Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in
- patients presenting without persistent ST-segment elevation. Eur Heart J. 2020 Aug 29; ehaa575.
- doi: 10.1093/eurheartj/ehaa575. Epub ahead of print. PMID: 32860058.
- 6. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP,
- Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M,
- Valgimigli M, Varenhorst C, Vranckx P, Widimský P; ESC Scientific Document Group. 2017
- ESC Guidelines for the management of acute myocardial infarction in patients presenting with
- 337 ST-segment elevation: The Task Force for the management of acute myocardial infarction in
- patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur
- Heart J. 2018; 39(2):119-177. doi: 10.1093/eurheartj/ehx393. PMID: 28886621.
- 8. Wessely R, Schömig A, Kastrati A. Sirolimus and Paclitaxel on polymer-based drug-eluting
- stents: similar but different. J Am Coll Cardiol. 2006; 47(4):708-714. doi:
- 342 10.1016/j.jacc.2005.09.047. Epub 2006 Jan 26. PMID: 16487832.
- 8. Patterson C, Mapera S, Li HH, Madamanchi N, Hilliard E, Lineberger R, Herrmann R,
- Charles P. Comparative effects of paclitaxel and rapamycin on smooth muscle migration and
- survival: role of AKT-dependent signaling. Arterioscler Thromb Vasc Biol. 2006; 26(7):1473-
- 346 1480. doi: 10.1161/01.ATV.0000223866.42883.3b. Epub 2006 Apr 27. PMID: 16645158.
- 9. Yazdani SK, Sheehy A, Pacetti S, Rittlemeyer B, Kolodgie FD, Virmani R. Stent Coating
- Integrity of Durable and Biodegradable Coated Drug Eluting Stents. J Interv Cardiol. 2016;
- 29(5):483-490. doi: 10.1111/joic.12303. Epub 2016 Jun 10. PMID: 27282892.
- 10. Costa F, Van Klaveren D, Feres F, James S, Räber L, Pilgrim T, Hong MK, Kim HS,
- Colombo A, Steg PG, Bhatt DL, Stone GW, Windecker S, Steyerberg EW, Valgimigli M;
- PRECISE-DAPT Study Investigators. Dual Antiplatelet Therapy Duration Based on Ischemic
- and Bleeding Risks After Coronary Stenting. J Am Coll Cardiol. 2019; 73(7):741-754. doi:
- 354 10.1016/j.jacc.2018.11.048. PMID: 30784667.

- 355 11. Saito Y, Kobayashi Y. Update on Antithrombotic Therapy after Percutaneous Coronary
- 356 Intervention Intern Med. 2020; 59(3):311-321. doi: 10.2169/internalmedicine.3685-19. Epub
- 357 2019 Oct 7. PMID: 31588089; PMCID: PMC7028427.
- 12. Windecker S, Mayer I, De Pasquale G, Maier W, Dirsch O, De Groot P, Wu YP, Noll G,
- Leskosek B, Meier B, Hess OM; Working Group on Novel Surface Coating of Biomedical
- 360 Devices (SCOL). Stent coating with titanium-nitride-oxide for reduction of neointimal
- 361 hyperplasia. Circulation. 2001; 104(8):928-933. doi: 10.1161/hc3401.093146. PMID: 11514381.
- 13. Ignarro LJ, Buga GM, Wei LH, Bauer PM, Wu G, del Soldato P. Role of the arginine-nitric
- oxide pathway in the regulation of vascular smooth muscle cell proliferation. Proc Natl Acad Sci
- 364 U S A. 2001; 98(7):4202-4208. doi: 10.1073/pnas.071054698. Epub 2001 Mar 20. PMID:
- 365 11259671; PMCID: PMC31203.
- 14. Windecker S, Simon R, Lins M, Klauss V, Eberli FR, Roffi M, Pedrazzini G, Moccetti T,
- Wenaweser P, Togni M, Tüller D, Zbinden R, Seiler C, Mehilli J, Kastrati A, Meier B, Hess OM.
- Randomized comparison of a titanium-nitride-oxide-coated stent with a stainless steel stent for
- 369 coronary revascularization: the TiNOX trial. Circulation. 2005; 111(20):2617-2622. doi:
- 370 10.1161/CIRCULATIONAHA.104.486647. Epub 2005 May 9. PMID: 15883209.
- 15. Huang X, Lin J, Demner-Fushman D. Evaluation of PICO as a knowledge representation for
- 372 clinical questions. AMIA Annu Symp Proc. 2006; 2006:359-363. PMID: 17238363; PMCID:
- 373 PMC1839740.
- 16. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions.
- www.cochrane-handbook.org, version 5.1.0 updated March 2011.
- 17. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M,
- Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews
- and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.
- 379 BMJ. 2009; 339:b2700. doi: 10.1136/bmj.b2700. PMID: 19622552; PMCID: PMC2714672.
- 18. Schünemann H, Brożek J, Guyatt G, Oxman A, editors. GRADE handbook for grading
- quality of evidence and strength of recommendations. Updated October 2013. The GRADE
- Working Group, 2013. Available from guidelinedevelopment.org/handbook.
- 19. Garcia-Garcia HM, McFadden EP, Farb A, Mehran R, Stone GW, Spertus J, Onuma Y,
- Morel MA, van Es GA, Zuckerman B, Fearon WF, Taggart D, Kappetein AP, Krucoff MW,
- Vranckx P, Windecker S, Cutlip D, Serruys PW; Academic Research Consortium.. Standardized
- 386 End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2
- 387 Consensus Document.. Eur Heart J. 2018 Jun 14;39(23):2392–2207. doi:
- 388 10.1093/eurheartj/ehy223.; PMID: 29897428.


- 20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-
- 390 88. doi: 10.1016/0197-2456(86)90046-2. PMID: 3802833.
- 391 21. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect
- and random-effects models for meta-analysis. Res Synth Methods. 2010; 1(2):97-111. doi:
- 393 10.1002/jrsm.12. Epub 2010 Nov 21. PMID: 26061376.
- 22. Karjalainen PP, Ylitalo A, Niemelä M, Kervinen K, Mäkikallio T, Pietili M, Sia J,
- Tuomainen P, Nyman K, Airaksinen KE. Titanium-nitride-oxide coated stents versus paclitaxel-
- eluting stents in acute myocardial infarction: a 12-months follow-up report from the TITAX
- 397 AMI trial. EuroIntervention. 2008; 4(2):234-241. doi: 10.4244/eijv4i2a42. PMID: 19110789.
- 398 23. Tuomainen PO, Ylitalo A, Niemelä M, Kervinen K, Pietilä M, Sia J, Nyman K, Nammas W,
- 399 Airaksinen KE, Karjalainen PP. Five-year clinical outcome of titanium-nitride-oxide-coated
- 400 bioactive stents versus paclitaxel-eluting stents in patients with acute myocardial infarction:
- 401 long-term follow-up from the TITAX AMI trial. Int J Cardiol. 2013; 168(2):1214-1219. doi:
- 402 10.1016/j.ijcard.2012.11.060. Epub 2012 Dec 3. PMID: 23218575.
- 403 24. Pilgrim T, Räber L, Limacher A, Löffel L, Wenaweser P, Cook S, Stauffer JC, Togni M,
- Vogel R, Garachemani A, Moschovitis A, Khattab AA, Seiler C, Meier B, Jüni P, Windecker S.
- 405 Comparison of titanium-nitride-oxide-coated stents with zotarolimus-eluting stents for coronary
- revascularization a randomized controlled trial. JACC Cardiovasc Interv. 2011; 4(6):672-682.
- 407 doi: 10.1016/j.jcin.2011.02.017. PMID: 21700254.
- 408 25. López-Mínguez JR, Nogales-Asensio JM, Doncel-Vecino LJ, Merchán-Herrera A, Pomar-
- Domingo F, Martínez-Romero P, Fernández-Díaz JA, Valdesuso-Aguilar R, Moreu-Burgos J,
- Díaz-Fernández J; members of the TITANIC XV Working Group. A randomized study to
- compare bioactive titanium stents and everolimus-eluting stents in diabetic patients (TITANIC
- 412 XV): 1-year results. Rev Esp Cardiol (Engl Ed). 2014; 67(7):522-530. doi:
- 413 10.1016/j.rec.2013.10.021. Epub 2014 Apr 3. PMID: 24952391.
- 26. Karjalainen PP, Nammas W, Ylitalo A, de Bruyne B, Lalmand J, de Belder A, Rivero-Crespo
- 415 F, Kervinen K, Airaksinen JKE. Long-term clinical outcome of titanium-nitride-oxide-coated
- stents versus everolimus-eluting stents in acute coronary syndrome: Final report of the BASE
- 417 ACS trial. Int J Cardiol. 2016; 222:275-280. doi: 10.1016/j.ijcard.2016.07.267. Epub 2016 Aug
- 418 1. PMID: 27497110.
- 27. Karjalainen PP, Niemelä M, Airaksinen JK, Rivero-Crespo F, Romppanen H, Sia J, Lalmand
- J, de Bruyne B, Debelder A, Carlier M, Nammas W, Ylitalo A, Hess OM; BACE-ACS study
- 421 investigators. A prospective randomised comparison of titanium-nitride-oxide-coated bioactive
- stents with everolimus-eluting stents in acute coronary syndrome: the BASE-ACS trial.
- 423 EuroIntervention. 2012; 8(3):306-315. doi: 10.4244/EIJV8I3A49. PMID: 22829506.

- 424 28. Colkesen EB, Eefting FD, Rensing BJ, Suttorp MJ, Ten Berg JM, Karjalainen PP, Van Der
- Heyden JA. TIDES-ACS Trial: comparison of titanium-nitride-oxide coated bio-active-stent to
- the drug (everolimus)-eluting stent in acute coronary syndrome. Study design and objectives.
- 427 Minerva Cardioangiol. 2015; 63(1):21-29. PMID: 25670057.
- 428 29. Tonino PAL, Pijls NHJ, Collet C, Nammas W, Van der Heyden J, Romppanen H, Kervinen
- K, Airaksinen JKE, Sia J, Lalmand J, Frambach P, Penaranda AS, De Bruyne B, Karjalainen PP;
- 430 TIDES-ACS Study Group. Titanium-Nitride-Oxide-Coated Versus Everolimus-Eluting Stents in
- 431 Acute Coronary Syndrome: The Randomized TIDES-ACS Trial. JACC Cardiovasc Interv. 2020;
- 432 13(14):1697-1705. doi: 10.1016/j.jcin.2020.04.021. PMID: 32703593.
- 433 30. Savović J, Weeks L, Sterne JA, Turner L, Altman DG, Moher D, Higgins JP. Evaluation of
- the Cochrane Collaboration's tool for assessing the risk of bias in randomized trials: focus
- groups, online survey, proposed recommendations and their implementation. Syst Rev. 2014;
- 436 3:37. doi: 10.1186/2046-4053-3-37. PMID: 24731537; PMCID: PMC4022341.
- 437 31. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ;
- 438 GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and
- 439 strength of recommendations. BMJ. 2008; 336(7650):924-926. doi:
- 440 10.1136/bmj.39489.470347.AD. PMID: 18436948; PMCID: PMC2335261.
- 32. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, Devereaux PJ,
- 442 Montori VM, Freyschuss B, Vist G, Jaeschke R, Williams JW Jr, Murad MH, Sinclair D, Falck-
- Ytter Y, Meerpohl J, Whittington C, Thorlund K, Andrews J, Schünemann HJ. GRADE
- guidelines 6. Rating the quality of evidence--imprecision. J Clin Epidemiol. 2011; 64(12):1283-
- 445 1293. doi: 10.1016/j.jclinepi.2011.01.012. Epub 2011 Aug 11. PMID: 21839614.
- 33. GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster
- 447 University, 2015 (developed by Evidence Prime, Inc.). Available from https://gdt.gradepro.org
- 448 34. Pogue JM, Yusuf S. Cumulating evidence from randomized trials: utilizing sequential
- monitoring boundaries for cumulative meta-analysis. Control Clin Trials. 1997; 18(6):580-593;
- discussion 661-6. doi: 10.1016/s0197-2456(97)00051-2. PMID: 9408720.
- 451 35. Seeger P, Gabrielsson A. Applicability of the Cochran Q test and the F test for statistical
- analysis of dichotomous data for dependent samples. Psychol Bull. 1968; 69(4):269-277. doi:
- 453 10.1037/h0025667. PMID: 5659656.
- 36. Gavaghan DJ, Moore RA, McQuay HJ. An evaluation of homogeneity tests in meta-analyses
- in pain using simulations of individual patient data. Pain. 2000; 85(3):415-424. doi:
- 456 10.1016/s0304-3959(99)00302-4. PMID: 10781914.
- 457 37. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;
- 458 21(11):1539-1558. doi: 10.1002/sim.1186. PMID: 12111919.

- 459 38. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-
- analyses. BMJ. 2003; 327(7414):557-560. doi: 10.1136/bmj.327.7414.557. PMID: 12958120;
- 461 PMCID: PMC192859.
- 39. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a
- simple, graphical test. BMJ. 1997; 315(7109):629-634. doi: 10.1136/bmj.315.7109.629. PMID:
- 464 9310563; PMCID: PMC2127453.
- 40. Egger M, Smith GD. Bias in location and selection of studies. BMJ. 1998; 316(7124):61-66.
- doi: 10.1136/bmj.316.7124.61. PMID: 9451274; PMCID: PMC2665334.
- 41. Sterne JAC, Egger M, Davey Smith G. Investigating and dealing with publication and other
- biases. In: Egger M, Davey Smith G, Altman DG (eds). Systematic Reviews in Health Care:
- Meta-Analysis in Context. London: BMJ Publishing Group, 2001:189-208.
- 42. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses
- of controlled trials with binary endpoints. Stat Med. 2006; 25(20):3443-3457. doi:
- 472 10.1002/sim.2380. PMID: 16345038.

474

- 475 Figure 1 PRISMA flow chart
- 476 Figure 2 Effectiveness endpoints
- 477 Figure 3 Safety endpoints



MACE 1-year	TiNOS		DES			Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	Year	M-H, Fixed, 95% Cl Year
ACS								
TITAX-AMI	22	214	27	211	19.9%	0.80 [0.47, 1.36]	2008	
BASE-ACS	40	417	37	410	27.3%	1.06 [0.69, 1.63]	2012	-
TIDES-ACS	62	989	35	502	33.9%	0.90 [0.60, 1.34]	2020	
Subtotal (95% CI)		1620		1123	81.1%	0.93 [0.72, 1.20]		•
Total events	124		99					
Heterogeneity: Chi ² = 0.70, df = 2 (P =	0.71); $I^2 = 0\%$							
Test for overall effect: Z = 0.55 (P = 0.5	58)							
Other CAD								
TIDE	27	152	21	150	15.4%	1.27 [0.75, 2.14]	2011	
TITANIC-XV	8	83	5	90	3.5%	1.73 [0.59, 5.09]	2011	
Subtotal (95% CI)		235		240	18.9%	1.36 [0.85, 2.17]		
Total events	35		26					
Heterogeneity: Chi ² = 0.26, df = 1 (P = 0	0.61); $I^2 = 0\%$							
Test for overall effect: Z = 1.27 (P = 0.2	?1)							
Total (95% CI)		1855		1363	100.00%	1.01 [0.81, 1.26]		+
Total events	159		125			- · · ·		
Heterogeneity: Chi ² = 2.79, df = 4 (P =	0.59); I ² = 0%							+ + + + + + + + + + + + + + + + + + + +
Test for overall effect: Z = 0.10 (P = 0.9	12)							0.2 0.5 1 2 5
Test for subgroup differences: Chi ² = 1.	.89, df = 1 (P :	= 0.17), I ² =	47.1%					Favours TiNOS Favours DES

clinically driven TLR 1-year	TiNOS		DES			Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	Year	M-H, Fixed, 95% CI Year
ACS								
TITAX-AMI	18	214	9	211	13.4%	1.97 [0.91, 4.29]	2008	
BASE-ACS	27	417	20	410	29.8%	1.33 [0.76, 2.33]	2012	 •
TIDES-ACS	53	989	17	502	33.3%	1.58 [0.93, 2.70]	2020	
Subtotal (95% CI)		1620		1123	76.4%	1.55 [1.10, 2.19]		-
Total events	98		46					
Heterogeneity: Chi ² = 0.67, df = 2 (P =	$= 0.72$); $I^2 = 0\%$							
Test for overall effect: Z = 2.48 (P = 0	.01)							
Other CAD								
TIDE	22	152	13	150	19.3%	1.67 [0.87, 3.19]	2011	
TITANIC-XV	7	83	3	90	4.2%	2.53 [0.68, 9.46]	2011	
Subtotal (95% CI)		235		240	23.6%	1.83 [1.02, 3.26]		
Total events	29		16					
Heterogeneity: Chi ² = 0.31, df = 1 (P =	$= 0.58$); $I^2 = 0\%$							
Test for overall effect: Z = 2.03 (P = 0	0.04)							
Total (95% CI)		1855		1363	100.00%	1.62 [1.20, 2.18]		
Total events	127		62			- · · · · ·		
Heterogeneity: Chi ² = 1.18, df = 4 (P =	= 0.88); I ² = 0%						_	
Test for overall effect: Z = 3.16 (P = 0	.002)							0.1 0.2 0.5 1 2 5 10
Test for subgroup differences: Chi ² =	0.22, df = 1 (P =	0.64), I ² =	0%					Favours TiNOS Favours DES

CD 1-year	TiNOS		DES			Risk Ratio			Ri	isk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	Year		M-H, Fixed, 95% CI Y		
ACS											
TITAX-AMI	1	214	4	211	21.6%	0.25 [0.03, 2.19]	2008		_	 	
BASE-ACS	8	417	4	410	21.6%	1.97 [0.60, 6.48]	2012		-		
TIDES-ACS	5	989	8	502	56.8%	0.32 [0.10, 0.96]	2020			_	
Subtotal (95% CI)		1620		1123	100.0%	0.66 [0.33, 1.31]					
Total events	14		16								
Heterogeneity: $Chi^2 = 5.67$, $df = 2$ (P = 0.	.06); I ² = 65%	6									
Test for overall effect: Z = 1.19 (P = 0.23	5)										
Other CAD											
TIDE	0	83	0	90		Not estimable	2011				
TITANIC-XV	0	152	0	150		Not estimable	2011				
Subtotal (95% CI)		235		240		Not estimable					
Total events	0		0								
Heterogeneity: Not applicable											
Test for overall effect: Not applicable											
Total (95% CI)		1855		1363	100.00%	0.66 [0.33, 1.31]			-		
Total events	14		16			- · · · •			_		
Heterogeneity: $Chi^2 = 5.67$, $df = 2$ (P = 0.	.06); I ² = 65%	6									——
Test for overall effect: Z = 1.19 (P = 0.23)							0.05	0.2	1 5	20
Test for subgroup differences: Not applic	able							Favou	irs TiNOS	Favours Di	ES

non-fatal MI 1-year	TiNOS		DES			Risk Ratio		Ris	sk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	Year	M-H, Fixe	d, 95% CI Year	
ACS										
TITAX-AMI	8	214	14	211	19.4%	0.56 [0.24, 1.32]	2008		+	
BASE-ACS	9	417	24	410	33.2%	0.37 [0.17, 0.78]	2012			
TIDES-ACS	18	989	17	502	31.0%	0.54 [0.28, 1.03]	2020		\dashv	
Subtotal (95% CI)		1620		1123	83.5%	0.48 [0.31, 0.73]		•		
Total events	35		55							
Heterogeneity: Chi ² = 0.72, df = 2 (P =	0.70); $I^2 = 0\%$									
Test for overall effect: Z = 3.41 (P = 0.0	0006)									
Other CAD										
TIDE	8	152	10	150	13.8%	0.79 [0.32, 1.95]	2011 -		 	
TITANIC-XV	1	83	2	90	2.6%	0.54 [0.05, 5.87]	2011		 	
Subtotal (95% CI)		235		240	16.5%	0.75 [0.32, 1.74]				
Total events	9		12					_		
Heterogeneity: Chi ² = 0.08, df = 1 (P =	0.77); $I^2 = 0\%$									
Test for overall effect: Z = 0.67 (P = 0.5	50)									
Total (95% CI)		1855		1363	100.00%	0.52 [0.36, 0.76]		•		
Total events	44		67			_		_		
Heterogeneity: Chi ² = 1.67, df = 4 (P =	0.80); $I^2 = 0\%$						+		+ + +	
Test for overall effect: Z = 3.37 (P = 0.0	0007)						0.05	5 0.2	1 5	10
Test for subgroup differences: Chi2 = 0	.89, df = 1 (P =	= 0.35), I ² =	0%					Favours TiNOS	Favours DE	ES

probable definite ST 1-year	TiNOS		DES			Risk Ratio		Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	Year		М-Н,	M-H, Fixed, 95% CI Year		
ACS								33				-
TITAX-AMI	1	214	8	211	21.1%	0.12 [0.02, 0.98]	2008	_	-			
BASE-ACS	5	417	11	410	29.0%	0.45 [0.16, 1.27]	2012		-	-		
TIDES-ACS	11	989	14	502	48.6%	0.40 [0.18, 0.87]	2020		_			
Subtotal (95% CI)		1620		1123	98.7%	0.35 [0.20, 0.64]			-			
Total events	17		33									
Heterogeneity: Chi ² = 1.28, df = 2 (P	= 0.53); I ² = 0%)										
Test for overall effect: Z = 3.41 (P = 0.	0006)											
Other CAD												
TITANIC-XV	0	83	0	90		Not estimable	2011					
TIDE	1	152	0	150	1.3%	2.96 [0.12, 72.11]	2011		-	-	-	
Subtotal (95% CI)		235		240	1.3%	2.96 [0.12, 72.11]				-		
Total events	1		0							1		
Heterogeneity: Not applicable												
Test for overall effect: Z = 0.67 (P = 0.	51)											
Total (95% CI)		1855		1363	100.0%	0.39 [0.22, 0.69]			4	•		
Total events	18		33			• •						
Heterogeneity: Chi ² = 2.81, df = 3 (P =	0.42); I ² = 0%							+		\rightarrow		
Test for overall effect: Z = 3.23 (P = 0.	.001)							0.005	0.1	1	10	200
Test for subgroup differences: Chi ² = 1	1.64, df = 1 (P :	= 0.20), I ² =	39.1%					Fav	ours TiNOS		Favours D	ES